Decipher Prostate | Post-RP Radiation Therapy

Filmed in September 2020 Backed by extensive clinical evidence, the Decipher® Prostate Genomic Classifier helps clinicians and their patients with prostate cancer make informed decisions for personalized treatment. Join Dr. Edouard Trabulsi, FACS, Professor and Vice Chair Department of Urology, and Dr. Robert Den, Associate Professor of Radiation Oncology, Thomas Jefferson University, as they discuss how genomic testing, like Decipher Prostate, can guide and inform multidisciplinary management of post-radical prostatectomy (RP) radiation therapy. Dr. Trabulsi and Dr. Den cover clinical data that informs decisions about early versus late radiation therapy for men with adverse pathology, along with prospective validation of the Decipher Prostate clinical utility and impact on treatment choices. They discuss how Decipher Prostate improves the ability to identify patients' risks for metastasis, prostate cancer-specific mortality, and overall survival, and through a series of case studies, they demonstrate the impact of genomic testing on treatment decisions in the post-RP setting. CHAPTERS 0:00 - Introduction 1:20 - Decipher Overview 3:20 - Clinical Data Background 6:00 - Guideline Support for Adjuvant/Early RT 10:00 - Reasons for Underutilization 13:00 - Importance of Endpoints 15:30 - Whole-Transcriptome Analysis 34:00 - Utility of Decipher Prostate 37:00 - RAVES and RADICALS Data 41:00 - pt3a Treatment Strategies 41:30 - Case Studies 57:00 - Key Points & Takeaways 59:00 - Q&A Learn more: Decipher Prostate | Intermediate Risk Prostate Cancer    • Decipher Prostate | Intermediate Risk Pros...